PurMinds: 'A Neuroscience Biopharma Company With A Robust Psychedelic Strategy'

This article was originally published on Microdose and appears here with permission.

Continuing our series of CEO interviews and company profiles, we sat down with Janet Qi, Founder and CEO of PurMinds Biopharma.

Since PurMinds may be new to many investors, why don’t we start with a brief introduction to the company?

“Sure, my pleasure. PurMinds is a biopharma company with a very robust psychedelic strategy. We have our own dealer’s license for controlled substances in Ontario, which is really the main real building block for us to start our two main channels.

One is the natural compound production facility. The other part of it is a neuroscience lab to focus on drug discovery and drug development. And our development focus is on neurological diseases, especially neurodegenerative diseases such as Alzheimer’s, ALS, vascular dementia, Parkinson’s, and other diseases.”

From your website, it says that PurMinds is “… a trailblazer, pursuing breakthrough solutions for devastating neurological diseases while setting the gold standards for research, development, and methodology”. So your company is primarily focused on neurodegenerative disease?

“Yes, we believe that for the next 50 years neurodegenerative diseases will be an increasingly serious issue and it has to be tackled. We are here to help and we want to make a difference.

We are using psychedelic non-psychedelic compounds, but I would say it’s psychedelics …

Full story available on Benzinga.com

More PurMinds: 'A Neuroscience Biopharma Company With A Robust Psychedelic Strategy'